V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10391574 | 10056889 | 1.58 | 59.9 | Palliative (P) | 2020-09-08 | 2020-10-01 | Trifluridine + Tipiracil | 02 | N | TIPIRACIL + TRIFLURIDINE | 100003974 |
| 10391683 | 10056891 | 1.7 | 75.4 | Curative (C) | 2019-12-01 | 2019-12-22 | Busulfan Oral | 02 | N | NIRAPARIB | 100472483 |
| 10391784 | 10056894 | 1.71 | 55.3 | Palliative (P) | 2020-06-17 | 2020-07-12 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | BUSULFAN | 100995757 |
| 10391787 | 10056895 | 1.78 | 70 | Curative (C) | 2019-03-01 | 2019-03-03 | CARBOPLATIN + VINORELBINE | 02 | N | CARBOPLATIN + VINORELBINE | 100899946 |
| 10391840 | 10056897 | null | 58.5 | null | 2022-05-14 | 2022-05-14 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101858657 |
| 10391931 | 10056898 | 1.68 | 0 | null | 2019-03-29 | 2019-04-06 | Cabazitaxel | 02 | null | CABAZITAXEL | 100976667 |
| 10391957 | 10056899 | 1.67 | 74 | null | 2000-03-13 | 2019-01-05 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100414287 |
| 10392325 | 10056905 | 1.71 | 66.4 | null | 2022-03-12 | 2022-03-15 | CISPLATIN + VINORELBINE | 02 | null | CETUXIMAB | 100748911 |
| 10392347 | 10056906 | 1.78 | 57.8 | Palliative (P) | 2016-10-14 | 2016-11-25 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | CHLORAMBUCIL + OBINUTUZUMAB | 101734816 |
| 10392471 | 10056908 | 1.69 | 81.6 | Neo-adjuvant (N) | null | 2017-02-11 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101015076 |
| 10392600 | 10056909 | 1.63 | 74.4 | Palliative (P) | 2019-12-20 | 2019-12-21 | Cabazitaxel | 02 | N | CABAZITAXEL | 100781718 |
| 10392648 | 10056911 | 1.88 | null | Palliative (P) | 2019-07-06 | 2019-09-29 | GDP | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100363288 |
| 10392729 | 10056912 | 1.69 | 65 | Palliative (P) | 2018-02-17 | 2018-10-29 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100025261 |
| 10392747 | 10056913 | 1.59 | 65 | Neo-adjuvant (N) | 2018-11-13 | 2019-09-05 | GEMCITABINE | 02 | N | GEMCITABINE | 100733102 |
| 10392926 | 10056915 | 1.77 | 59.4 | Palliative (P) | 2020-08-05 | 2020-08-05 | Trifluridine + Tipiracil | 02 | N | TIPIRACIL + TRIFLURIDINE | 100659922 |
| 10392961 | 10056916 | 1.74 | 66 | 03 | 2019-09-01 | 2019-09-15 | DABRAFENIB + TRAMETINIB | null | N | DABRAFENIB + TRAMETINIB | 101666642 |
| 10393347 | 10056919 | 1.8 | 87.1 | Palliative (P) | 2017-11-13 | 2017-11-20 | DABRAFENIB | 02 | null | ACALABRUTINIB | 100725246 |
| 10393501 | 10056920 | 1.6 | null | 03 | 2018-07-19 | 2018-07-19 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101860313 |
| 10393632 | 10056921 | 1.75 | 71.4 | Palliative (P) | 2020-12-04 | 2021-01-15 | AFATINIB | 02 | N | AFATINIB | 100930069 |
| 10393729 | 10056922 | 0 | 71 | null | 2018-07-16 | 2018-07-16 | Capecitabine (21 day) + Irinotecan | 02 | null | ACALABRUTINIB | 101140195 |
| 10393798 | 10056923 | 1.67 | 56.4 | null | 2020-02-20 | 2020-02-20 | Bortezomib +/- Dexamethasone | 02 | null | BORTEZOMIB | 100784295 |
| 10393881 | 10056924 | 1.74 | 88.4 | Palliative (P) | 2018-09-14 | 2018-11-03 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | CHLORAMBUCIL + OBINUTUZUMAB | 101109475 |
| 10393924 | 10056925 | 1.66 | 91.75 | Palliative (P) | 2019-08-05 | 2019-08-06 | Carboplatin + Liposomal Doxorubicin | 02 | N | BUSULFAN | 100544328 |
| 10393926 | 10056926 | 1.64 | 73 | Palliative (P) | 2017-02-19 | 2017-03-04 | DABRAFENIB | 02 | null | BORTEZOMIB + THALIDOMIDE | 101412472 |
| 10394017 | 10056927 | 1.76 | 57 | null | 2020-03-12 | 2020-03-12 | Trifluridine + Tipiracil | 02 | null | TIPIRACIL + TRIFLURIDINE | 100469794 |
| 10394078 | 10056929 | 0 | null | Palliative (P) | 2019-01-05 | 2019-01-05 | Vinorelbine (weekly iv) | 02 | null | FLUOROURACIL | 100787896 |
| 10394092 | 10056930 | 1.78 | 68.25 | null | 2004-05-20 | 2020-07-29 | Trifluridine + Tipiracil | 02 | Y | TIPIRACIL + TRIFLURIDINE | 101218214 |
| 10394095 | 10056931 | 1.84 | 80.8 | null | 2019-12-17 | 2019-12-17 | CETUXIMAB + RT | 02 | null | VINORELBINE | 101313413 |
| 10394137 | 10056933 | 1.7 | 63 | Palliative (P) | 2019-08-26 | 2019-08-26 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | CHLORAMBUCIL + OBINUTUZUMAB | 100077605 |
| 10394288 | 10056937 | 1.71 | 80 | Palliative (P) | 2021-08-06 | 2021-09-20 | PERTUZUMAB + TRASTUZUMAB | 02 | N | FLUOROURACIL | 101406219 |
| 10394305 | 10056938 | 1.54 | null | Palliative (P) | 2012-04-25 | 2019-03-20 | PERTUZUMAB + TRASTUZUMAB | 02 | N | CISPLATIN | 100722742 |
| 10394309 | 10056939 | 1.67 | 68.7 | Palliative (P) | 2018-06-06 | 2018-06-08 | Bortezomib (weekly) | null | N | BORTEZOMIB | 100658864 |
| 10394438 | 10056941 | null | null | null | 2017-01-03 | 2017-01-13 | BUSULFAN | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101616712 |
| 10394516 | 10056942 | 1.67 | 67 | null | 2019-12-05 | 2019-12-05 | Niraparib | 02 | null | BORTEZOMIB + THALIDOMIDE | 101465613 |
| 10394555 | 10056943 | null | 68.8 | 03 | 2018-10-01 | 2019-02-01 | CVP R | 02 | N | DABRAFENIB | 101766674 |
| 10394712 | 10056944 | 1.81 | 100 | 03 | 2017-03-16 | 2018-02-04 | CETUXIMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 101013147 |
| 10394802 | 10056945 | 1.81 | 52.1 | Curative (C) | 2013-06-04 | 2019-01-01 | DABRAFENIB + TRAMETINIB | 99 | N | DABRAFENIB + TRAMETINIB | 100768299 |
| 10395191 | 10056948 | null | null | Palliative (P) | 2018-08-06 | 2020-08-21 | Cytarabine HD + Rituximab | 01 | N | DOXORUBICIN + OLARATUMAB | 100242839 |
| 10395217 | 10056950 | 1.7 | 71.6 | null | 2018-11-10 | 2019-01-09 | AML 18 TRIAL | 02 | null | AML19 TRIAL | 101223728 |
| 10395368 | 10056951 | 1.61 | null | Palliative (P) | null | 2021-01-17 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 01 | N | BUSULPHAN | 100575933 |
| 10395391 | 10056952 | 1.56 | 69.05 | Neo-adjuvant (N) | 2019-05-13 | 2019-11-04 | null | N | N | LENVATINIB | 100933024 |
| 10395611 | 10056953 | 1.7 | 87.6 | null | 2016-05-03 | 2018-09-21 | EVEROLIMUS | null | null | DOCETAXEL + NINTEDANIB | 100710720 |
| 10395783 | 10056954 | 1.78 | 67 | null | 2017-05-17 | 2017-05-17 | Cyclophosphamide + Docetaxel | 02 | N | GEMTUZUMAB OZOGAMICIN | 100563493 |
| 10396037 | 10056955 | 1.8 | 108.4 | null | 2020-04-27 | 2020-05-03 | Doxorubicin + Olaratumab | 02 | null | PLATFORM TRIAL | 101297943 |
| 10396318 | 10056958 | 1.63 | 80 | Curative (C) | 2019-08-16 | 2019-11-28 | ABEMACICLIB + FULVESTRANT | 02 | N | ABEMACICLIB | 100462041 |
| 10396463 | 10056959 | 1.56 | 62.4 | null | 2019-04-05 | 2019-04-05 | Liposomal Doxorubicin 40mg/m2 | 02 | null | SUNITINIB | 100299489 |
| 10396550 | 10056960 | null | null | null | 2020-04-22 | 2020-04-27 | Obinutuzumab + Venetoclax | 02 | null | TRASTUZUMAB EMTANSINE | 101322404 |
| 10396943 | 10056961 | 1.7 | 91.6 | 03 | null | 2018-05-04 | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 2 | N | DOXORUBICIN + IFOSFAMIDE | 101240498 |
| 10396967 | 10056962 | null | null | null | 2020-04-06 | 2020-04-06 | EVEROLIMUS | 02 | null | BRENTUXIMAB | 100624856 |
| 10397323 | 10056966 | 1.85 | 70.1 | null | null | 2017-02-19 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | null | TOPOTECAN | 101420043 |